Aktsiaselts Infortar acquired its own shares on the Nasdaq Tallinn Stock Exchange during the period of 7 September – 11 September 2026 as follows:

Date Aggregated volume (pcs) Weighted average price per day (EUR)
07.09.2026 216 57,6778
08.09.2026 222 58,1369
09.09.2026 225 60,0000
10.09.2026 227 60,0000
11.09.2026 230 60,0000

Aktsiaselts Infortar is acquiring its own shares based on the stock exchange announcement published on 20 April 2026. The share buyback programme is managed by SEB Pank AS, which will buy back shares on behalf of Aktsiaselts Infortar.

Summary data (daily volume and weighted average prices) will be disclosed no later than on the seventh trading day following the transaction and be made available to the Estonian Financial Supervision and Resolution Authority, via the Nasdaq Tallinn system, and on Aktsiaselts Infortar´s investor website.

Further detailed information on the transactions is attached.

Infortar operates in seven countries, the company’s main fields of activity are maritime transport, energy and real estate. Infortar owns a 68.83% shareholding in Tallink Grupp, a 100% share in Elenger Grupp and a versatile and modern real estate portfolio of approx. 141,000 m2. In addition to the three main areas of activity, Infortar also operates in construction and mineral resources, agriculture, and other areas. A total of 107 companies belong to the Infortar group, including 3 associates and 2 subsidiaries of associates. Infortar employs 6890 people.

Additional information:

Kadri Laanvee
Investor Relations Manager
Phone: +372 5156662
e-mail: kadri.laanvee@infortar.ee
www.infortar.ee/en/investor

Attachment

  • Secured a substantial order to supply gas compression systems for the Cloud Connector Pipeline project
  • Awarded a major order for a modular liquefaction solution supporting Plaquemines LNG facility expansion
  • Awards deepen long-standing strategic collaboration with Venture Global

HOUSTON and LONDON, Sept. 13, 2026 (GLOBE NEWSWIRE) — Baker Hughes (NASDAQ: BKR) and Venture Global LNG are expanding their long-standing collaboration to advance critical U.S. gas infrastructure. Reinforcing Baker Hughes’ connected capabilities across the natural gas value chain, the company will provide gas compression systems for the Cloud Connector Pipeline project in Louisiana, as well as a modular liquefaction solution including cold boxes to support the expansion of the Plaquemines LNG facility.

Together, the pipeline and liquefaction awards demonstrate the critical role of integrated natural gas infrastructure in expanding LNG supply and enhancing energy security for global markets. The substantial pipeline award, which includes 13 gas compression systems driven by Frame 5/2E gas turbines, represents one of the largest deployments for LNG feed gas transportation in the United States. This will enable reliable and efficient transportation of feed gas through the Cloud Connector Pipeline to Venture Global’s Plaquemines facility.

Under the major liquefaction award, Baker Hughes will provide four liquefaction blocks, comprising a total of eight liquefaction modules, to support additional LNG production capacity at Plaquemines LNG facility. The liquefaction blocks include Chart cold boxes.

“Baker Hughes has been a trusted partner across our LNG developments, both at our LNG facilities and across our pipeline infrastructure,” said Mike Sabel, CEO of Venture Global. “As we advance the expansion of Plaquemines LNG, this collaboration not only supports our expansion plans, but also helps ensure we deliver the reliable feed gas transportation necessary to realize our mission of supplying secure LNG to global markets.”

“U.S. natural gas is helping to deliver the energy continuity required for industries, communities, and economies to thrive, grow and innovate. Baker Hughes is proud to work alongside our partners at Venture Global as they expand Plaquemines LNG, providing the critical energy infrastructure needed to meet growing global long-term global energy demand,” said Lorenzo Simonelli, chairman and CEO of Baker Hughes.

The liquefaction solution provided by Baker Hughes for the Plaquemines expansion follows a similar scope recently awarded for the CP2 project. Each liquefaction block is based on two electric-motor driven, single mixed-refrigerant (SMR) liquefaction modules and associated compression trains featuring Baker Hughes’ advanced centrifugal compressor technology, as well as cold boxes, air coolers and integrated control systems.

The Cloud Connector award is the second order of Frame 5/2E gas turbine-driven centrifugal compressor packages for Venture Global’s feed gas pipeline, expanding the fleet to 23 Frame 5/2E-driven gas compression systems for the Plaquemines LNG facility. The award further strengthens Baker Hughes’ strategic relationship with Venture Global, supporting more than 100 MTPA of existing and planned LNG production capacity, and reinforces Baker Hughes’ role as a leading industrialized energy provider across the natural gas value chain.

About Baker Hughes
Baker Hughes (NASDAQ: BKR) is an energy technology company that provides solutions to energy and industrial customers worldwide. Built on a century of experience and conducting business in over 120 countries, our innovative technologies and services are taking energy forward – making it safer, cleaner and more efficient for people and the planet. Visit us at bakerhughes.com.

For more information, please contact:

Media Relations

Adrienne M. Lynch
+1 713-906-8407
adrienne.lynch@bakerhughes.com

Investor Relations

Chase Mulvehill
+1 346-297-2561
investor.relations@bakerhughes.com

Agreement brings delayed and real-time OTC Link pricing to CITIC Securities Brokerage (HK) Limited’s Hong Kong clients through its trading platforms

NEW YORK, Sept. 13, 2026 (GLOBE NEWSWIRE) — OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced a market data licensing agreement with CITIC Securities Brokerage (HK) Limited, a subsidiary of CITIC Securities International, the international arm of CITIC Securities.

Under the agreement, CITIC Securities Brokerage (HK) Limited will distribute OTC Markets pricing data to clients through its browser-based trading platform and mobile application. Delayed Level 1 quote data from OTC Link ATS, OTC Markets’ primary trading venue for US OTC equity securities, will be available on a 15-minute delayed basis from 6:00 a.m. to 5:00 p.m. Eastern time as a baseline offering to CITIC Securities Brokerage (HK)’s broader client base. Real-time Level 1 data will be available to premium subscribers, giving those clients direct visibility into live U.S. quote and trade activity.

The agreement extends OTC Markets pricing data to CITIC Securities Brokerage (HK) Limited’s retail client base across Hong Kong, connecting investors with data on more than 12,000 securities quoted across OTC Markets’ OTCQX, OTCQB, OTCID and Pink Limited markets, including international companies from Euronext, LSE, TSE, ASX and other exchanges that are cross-traded in the U.S.

“Investors in Hong Kong are asking for more visibility into their U.S.-traded interests,” said Matt Fuchs, EVP, Head of Market Data at OTC Markets Group. “This agreement gives CITIC Securities Brokerage (HK)’s clients access to key quote data on more than 12K global names traded in USD.”

“Access to reliable U.S. market data is part of how we serve clients who invest globally,” said Alan Fan, Chief Operating Officer of CITIC Securities Brokerage (HK) Limited. “This agreement strengthens that offering across our key trading platforms.”

The agreement reflects the growing demand for OTC Markets’ data capabilities in the Asia-Pacific region. In May, JP Chan was appointed Senior Vice President and Regional Head, Asia-Pacific, to lead the company’s growth across the region from Hong Kong.

International companies represent more than 90% of total dollar volume traded on OTC Markets, and demand for that data among investors outside the U.S. continues to grow.

About OTC Markets Group Inc.

OTC Markets Group Inc. (OTCQX: OTCM) operates regulated markets for trading 12,000 U.S. and international securities. Our data-driven disclosure standards form the foundation of our public markets: OTCQX® Best Market, OTCQB® Venture Market, OTCID™ Basic Market, and Pink Limited™ Market.

Our OTC Link® Alternative Trading Systems (ATSs) provide critical market infrastructure that broker-dealers rely on to facilitate trading. Our innovative model offers companies more efficient access to the U.S. financial markets.

OTC Link ATS, OTC Link ECN, OTC Link NQB, and MOON ATS® are each an SEC-regulated ATS, operated by OTC Link LLC, a FINRA and SEC-registered broker-dealer, member SIPC.

To learn more about how we create better informed and more efficient markets, visit www.otcmarkets.com.

About CITIC Securities Brokerage (HK) Limited

CITIC Securities Brokerage (HK) Limited is the Hong Kong wealth management platform of CITIC Securities, a leading Chinese investment bank with top-tier asset management scale. It primarily provides diversified, multi-market asset allocation solutions to high-net-worth individuals and corporate clients, with products and services covering multiple asset classes including funds, trusts, bonds, structured investment products, securities and futures.

Media Contact:

OTC Markets Group Inc.
Phone: (212) 896-4428
Email: media@otcmarkets.com

The Board of Directors of Kvika banki has appointed Jón Birgir Jónsson as Chief Executive Officer of Kvika banki. Jón Birgir will assume his new role on 1 December 2026, succeeding Ármann Þorvaldsson, who announced earlier this year his intention to step down as CEO.

Jón Birgir brings extensive experience from international financial markets, having spent most of his career in London and New York with two leading global asset management firms.

From 2013 to 2025, Jón Birgir was with Neuberger Berman in London, where he was a Partner and held a senior management role. He joined the firm to strengthen its global fixed income capabilities and subsequently took on broader responsibilities, including the management of relationships with professional and institutional investors. Prior to joining Neuberger Berman, he worked at J.P. Morgan Asset Management from 1998, in both New York and London, as a portfolio manager specialising in fixed income and global interest rate markets.

Jón Birgir holds a bachelor’s degree in mathematics from the University of Iceland and a graduate degree in financial engineering from New York University. While having spent much of his professional career abroad, he has maintained strong ties with the Icelandic business community, including through his service on the Board of the British-Icelandic Chamber of Commerce.

Company Announcement

Copenhagen, 13 September 2026
No. 57/2026

NEW MID-TERM FINANCIAL TARGETS – ISS TO ACCELERATE HIGHER-QUALITY GROWTH AND EXPAND MARGINS

ISS A/S, a global leader in workplace experience and facility services, today announces new mid-term financial targets for 2026-2028 to be presented at the Capital Markets Day tomorrow.

ISS A/S is targeting the following new mid-term financial targets for 2026-2028 (replacing targets announced in November 2022):

  • Average annual organic growth above 5%, measured over the period 2026-2028  
  • Operating margin1) between 5.5-6.0% in 2028
  • Cash conversion of above 60%

Like-for-like growth (volume growth and net new wins) is expected to contribute a larger share of organic growth going forward, while price increases are expected to represent a reduced share of growth compared to 2026 levels. Projects and above-base is expected to be a decent contributor to organic growth in the period.

The 2026 Outlook, as stated in the Interim Report for H1 2026 on 11 August 2026, is unchanged.

Details on the Capital Markets Day held on 14 September 2026 can be found at ISS Investor Relations website (ISS Capital Markets Day 2026). The presentation material will be released before 09.00 CET on 14 September.

This announcement contains publication of inside information pursuant to Article 17 of the EU Market Abuse Regulation.

Note: 1) Operating margin before other items, excl IAS 29

         

For investor enquiries
Michael Vitfell-Rasmussen, Head of Group Investor Relations, +45 53 53 87 25
Anne Sophie Riis, Senior Investor Relations Manager, +45 30 52 94 68

For media enquiries
Charlotte Holm, Head of External Communication, +45 41 76 19 89

ISS is a leading, global provider of workplace and facility service solutions. In partnership with customers, ISS drives the engagement and well-being of people, minimises the impact on the environment, and protects and maintains property. ISS brings all of this to life through a unique combination of data, insight and service excellence at offices, factories, airports, hospitals and other locations across the globe. ISS has more than 325,000 employees around the globe, who we call “placemakers”. In 2025, Group revenue was DKK 84.7 billion. For more information on the ISS Group, visit www.issworld.com

Attachment

  • Tambotatug pelitecan (Tam-Peli) demonstrated statistically significant efficacy over topotecan in a phase III study conducted in China, reducing the risk of death by 54% and disease progression by 71%, while achieving an objective response rate of 59.1% vs 9.7%1
  • The novel B7-H3-targeted antibody-drug conjugate with a dual release mechanism of the payload is based on MediLink’s proprietary TMALIN® platform, designed to maximise antitumour activity while minimising off-target toxicity2,3
  • Roche is developing and commercialising Tam-Peli outside mainland China, Hong Kong, and Macau across multiple tumour types, with plans to rapidly initiate global trials
  • Tam-Peli has received U.S. FDA and China CDE Breakthrough Therapy Designations for relapsed small-cell lung cancer (SCLC)

Basel, 13 September 2026 – Roche (SIX: RO, ROP; OTCQX: RHHBY) today announced that its collaborator MediLink released interim results from the randomised phase III TAISHAN-302 trial evaluating Tam-Peli (tambotatug pelitecan, YL201) versus topotecan in Chinese patients with relapsed small-cell lung cancer (SCLC) who progressed after prior platinum-based chemotherapy with or without a PD-L1 inhibitor.1 The trial met its primary endpoint of overall survival (OS) with Tam-Peli demonstrating a statistically significant and clinically meaningful OS benefit, reducing the risk of death by 54% (median OS 13.3 vs. 9.4 months; stratified HR=0.46; p<0.0001). Tam-Peli also showed robust efficacy across secondary endpoints, significantly extending progression-free survival (PFS) (median PFS 7.4 vs. 2.8 months) and response rates (59.1% vs. 9.7%) compared to standard-of-care topotecan.1

The trial results are being presented as a Late-Breaking Abstract during a Presidential Presentation at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC) in Seoul with simultaneous publication in The New England Journal of Medicine.1 Additionally, the Center of Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) has accepted the New Drug Application (NDA) for filing.

“The second positive phase III trial for Tam-Peli, TAISHAN-302, reinforces our confidence in its potential to improve outcomes for people with cancer,” said Levi Garraway, MD, PhD, Roche’s Chief Medical Officer and Head of Global Product Development. “These data demonstrate clinically meaningful survival and response rate improvements in an aggressive and hard-to-treat disease, supporting our plans to initiate global phase III trials quickly.”

Key efficacy results from the phase III TAISHAN-302 trial1

Primary and key secondary endpoints Tam-Peli (n=225) Topotecan (n=226) Hazard Ratio / (95% CI) p-value
Median OS in months 13.3 9.4 HR 0.46 (0.35–0.62) p < 0.0001
Median PFS in months 7.4 2.8 HR 0.29 (0.23–0.37) p < 0.0001
Confirmed Objective Response Rate (%) 59.1 9.7 — p < 0.0001

Consistent OS and PFS improvements were observed across prespecified subgroups, including age, chemotherapy-free interval (<90 vs. ≥90 days), and baseline liver or brain metastatic status. In patients with baseline brain metastases, Tam-Peli extended median intracranial PFS (6.1 months vs. 4.2 months; unstratified HR=0.43; 95% CI: 0.27–0.68) and achieved a higher intracranial response rate (32.4% vs. 2.9%).1

Tam-Peli showed a favourable and manageable safety profile, demonstrating lower rates of Grade ≥3 treatment-related adverse events (TRAEs) compared with topotecan (46.4% vs. 74.7%). Serious TRAEs occurred in 25.9% of patients receiving Tam-Peli versus 36.4% with topotecan. Treatment-emergent interstitial lung disease (ILD/pneumonitis) across all grades occurred in 4.9% of Tam-Peli patients versus 1.4% with topotecan; grade 3 ILD/pneumonitis events were low in both groups (0.9% each), with no Grade 4 or 5 events reported.1

Tam-Peli is designed to target B7-H3, a protein broadly expressed in solid tumours but minimally in normal tissue, allowing it to target cancer cells with high selectivity. Built on MediLink’s TMALIN® platform, its stable linker and dual-release mechanism are designed to  maximise therapeutic efficacy while limiting off-target toxicity.2,3

Following the positive phase III TAISHAN-301 trial (NCT06629597) in nasopharyngeal carcinoma, TAISHAN-302 represents the second positive phase III readout for Tam-Peli, conducted in patients in China. Under a collaboration and exclusive licensing agreement between Roche and MediLink Therapeutics, Roche holds development, manufacturing, and commercialisation rights for Tam-Peli worldwide, outside mainland China, Hong Kong, and Macau. Roche is advancing clinical development in its licensed territories across multiple solid tumour types and plans to rapidly initiate global phase III trials.

About the TAISHAN-302 study
TAISHAN-302 (NCT06612151) is a randomised, open-label phase III study evaluating the efficacy and safety of Tam-Peli (2.0 mg/kg intravenously on day 1 of each 21-day cycle, maximum dose 200 mg) compared with topotecan in patients with small-cell lung cancer (SCLC) who have progressed after one prior line of platinum-based chemotherapy with or without a PD-L1 inhibitor. The trial enrolled 451 patients across 85 study sites in China. The primary endpoint of the trial is overall survival (OS). Key secondary endpoints include investigator-assessed progression-free survival (PFS) and objective response rate (ORR), alongside disease control rate (DCR), duration of response (DoR), time to response (TTR), safety, pharmacokinetics, and immunogenicity.1

About tambotatug pelitecan (Tam-Peli; YL201)
Tambotatug pelitecan (Tam-Peli; YL201) is an investigational antibody-drug conjugate (ADC) targeting B7-H3, a protein highly expressed across various solid tumours, both on the tumour cells and in the microenvironment, but limited in healthy tissues.1,2 Utilising MediLink Therapeutics’ TMALIN® (Tumour Microenvironment-Activatable Linker) platform, Tam-Peli links a B7-H3-specific monoclonal antibody to a novel topoisomerase 1 inhibitor payload with a drug-to-antibody ratio (DAR) of 8. By combining a stable, hydrophilic linker with a dual-release mechanism, Tam-Peli is designed to deliver its cytotoxic payload both inside tumour cells as well as extracellularly in the tumour microenvironment, maximising therapeutic efficacy while minimising systemic toxicity.2,3

Beyond SCLC, Tam-peli holds two U.S. Food and Drug Administration (FDA) Orphan Drug Designations and three China Center of Drug Evaluation (CDE) Breakthrough Therapy Designations (BTDs) across additional indications, including nasopharyngeal carcinoma (NPC), esophageal squamous cell carcinoma (ESCC), and pancreatic cancer.

In January 2026, Roche entered into an exclusive licensing agreement with MediLink Therapeutics for the development, manufacturing, and commercialisation of Tam-Peli worldwide, excluding mainland China, Hong Kong SAR and Macau.

About Roche in lung cancer
Lung cancer remains the leading cause of cancer-related deaths worldwide, surpassing the combined mortality rates of breast, prostate, and stomach cancers. Each year, it claims the lives of 1.8 million people. SCLC accounts for 15% of lung cancer diagnoses.4 It is a highly aggressive form of lung cancer which progresses rapidly, regardless of the stage of disease at diagnosis. Despite advances in first-line treatment, SCLC frequently relapses or progresses and outcomes remain poor for many people with recurrent disease, highlighting the continued need for more effective treatment options.

Roche is committed to advancing the field of lung cancer treatments, leveraging more than 20 years of scientific expertise to improve patient outcomes. Roche’s portfolio includes approved medicines such as Alecensa® (alectinib), Tecentriq® (atezolizumab), and Rozlytrek® (entrectinib). Its extensive pipeline includes investigational treatments across three key focus areas: small-cell lung cancer, non-small cell lung cancer (NSCLC) with actionable genomic alterations (AGA), and NSCLC without AGA.

About Roche
Roche (SIX: RO, ROP; OTCQX: RHHBY) is a healthcare company uniquely placed to prevent, stop and cure diseases by uniting leading science and technology across diagnostics, medicines and digital solutions. Roche was founded in Basel, Switzerland in 1896 and today is a leading provider of transformative medicines and diagnostics for millions of people in over 150 countries around the world. It is dedicated to tackling healthcare challenges that place the greatest strain on patients, families, communities and healthcare systems. Across its Diagnostics and Pharmaceutical divisions, Roche focuses on areas including oncology, neurology, cardiovascular and metabolic diseases, ophthalmology, infectious diseases and immunology with the aim of providing real and positive change for patients, the people they love and the professionals who care for them.
Genentech in the United States is a fully owned subsidiary in the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, a major innovator in the Japanese therapeutic antibody market.

For more information, please visit www.roche.com.

All trademarks used or mentioned in this release are protected by law.

References
[1] Zhang L, Zhao Y, Liu H, et al. Tam-Peli, an Anti-B7-H3 Antibody-Drug Conjugate, Versus Topotecan in Relapsed SCLC: A Randomized, Open-Label, Phase 3 Study (TAISHAN-302). WCLC 2026: Abstract PL02.03.
[2] Xu J, et al. Cancer Res. 2023;83:6304.
[3] Ma Y, et al. Nat Med. 2025;31:1949-1957.
[4] Rudin CM, et al. Small-cell lung cancer. Nat Rev Dis Primers. 2021;7(1):3.

Roche Global Media Relations
Phone: +41 61 688 88 88 / e-mail: media.relations@roche.com

Tristan Schmitz
Phone: +41 79 529 70 35
Lorena Corfas
Phone: +41 79 568 24 95

 

Simon Goldsborough
Phone: +44 797 32 72 915
Karsten Kleine
Phone: +41 79 461 86 83

 

Kirti Pandey
Phone: +41 79 398 38 53
Yvette Petillon
Phone: +41 79 961 92 50

 

Irène Stephan
Phone: +41 79 377 83 75
Albert Thottiyil
Phone: +41 79 775 66 12

Roche Investor Relations

Dr Bruno Eschli
Phone: +41 61 68-75284
e-mail: bruno.eschli@roche.com
Dr Sabine Borngräber
Phone: +41 61 68-88027
e-mail: sabine.borngraeber@roche.com

 

Dr Birgit Masjost
Phone: +41 61 68-84814
e-mail: birgit.masjost@roche.com
 

Investor Relations North America

Loren Kalm
Phone: +1 650 225 3217
e-mail: kalm.loren@gene.com

 

Attachment

Media Relations
Sam Connatty
Tel.: +44 (0) 7811 486517
E-Mail: sam.connatty@capgemini.com

Investor Relations:
Vincent Biraud
Tel.: +33 1 47 54 50 87
E-mail: vincent.biraud@capgemini.com

Capgemini signs a definitive agreement to sell Capgemini Government Solutions

Paris, September 12, 2026 – Capgemini today announces that it has entered into an agreement with ITC Federal, a US IT solutions and enterprise services provider to federal law enforcement, homeland security and defense agencies, for the sale of Capgemini Government Solutions, its subsidiary working with the US federal government.

This transaction is expected to close in the coming weeks, subject to customary conditions for a transaction of this nature.

As indicated when the Group announced the launch of the divestment process earlier this year, Capgemini Government Solutions represented 0.4% of the Group’s global 2025 revenue and less than 2% of its US revenue.

About Capgemini
Capgemini is the business transformation partner for enterprises in the age of AI. We help organizations imagine and build an intelligent, sustainable future, combining AI, technology and human ingenuity to transform how they operate, innovate and grow. With unique end-to-end capabilities spanning strategy, technology, engineering and intelligent operations, we bring together deep industry expertise and market-leading capabilities in AI, cloud and data to turn ambition into measurable business outcomes at scale. Supported by a robust ecosystem of partners and nearly 60 years of expertise, Capgemini is a responsible and diverse global organization of over 410,000 team members in more than 50 countries. The Group reported 2025 revenues of €22.5 billion.

Make it real | www.capgemini.com

Attachment

CALGARY, Alberta, Sept. 11, 2026 (GLOBE NEWSWIRE) — Computer Modelling Group Ltd. (“CMG” or the “Company”) announced today the voting results from its annual general meeting of shareholders (the “Meeting”) held on September 10, 2026. A total of 52,937,297 votes were represented in person or by proxy at the Meeting, constituting approximately 67.87% of the Company’s total issued and outstanding common shares as of the record date.

All of the matters put forward before shareholders for consideration and approval as set out in the Company`s Management Information Circular dated July 31, 2026 (the “Circular”) were approved by the shareholders. Each of the seven director nominees was elected as a director of CMG. Detailed results of the vote are set out below.

  Voted For % For Votes
Withheld
% Withheld
ALEXANDER M. DAVERN 48,058,532 97.37% 1,298,988 2.63%
ANUROOP DUGGAL 49,315,210 99.91% 42,310 0.09%
PRAMOD JAIN 50,095,630 99.48% 261,890 0.52%
PETER H. KINASH 40,118,355 81.28% 9,239,165 18.72%
ANDREW PASTOR 47,632,214 96.50% 1,725,306 3.50%
BIRGIT TROY 49,063,327 99.40% 294,193 0.60%
CHRISTOPHER WRIGHT 49,101,675 99.48% 255,845 0.52%

Additionally, all other resolutions put to shareholders, being the appointment of Deloitte LLP as the Company’s auditor, the amendments to the Company’s Amended and Restated Stock Option Plan (2020) and approval of the unallocated stock options thereunder and the amendments to the Company’s Amended and Restated Performance Share Unit and Restricted Share Unit Plan (2020) and approval of the unallocated awards thereunder, were duly passed at the Meeting. Further details on the other resolutions can be found in the report of voting results and the Circular which are available under the Company’s profile on SEDAR+ at www.sedarplus.ca.

CMG (TSX:CMG) is a global software and consulting company that combines science and technology with deep industry expertise to solve complex subsurface and surface challenges for the new energy industry around the world. CMG is headquartered in Calgary, AB, with offices in Houston, Oslo, Stavanger, Kaiserslautern, Oxford, Dubai, Bogota, Rio de Janeiro, Bengaluru, and Kuala Lumpur. For more information, please visit www.cmgl.ca.

For further information, please contact:

Kim MacEachern
Director, Investor Relations
cmg-investors@cmgl.ca

IRVINE, Calif., Sept. 11, 2026 (GLOBE NEWSWIRE) — Skyworks Solutions, Inc. (Nasdaq: SWKS) (“Skyworks”), a leading developer, manufacturer and provider of analog and mixed-signal semiconductors and solutions for numerous applications, today announced that it has extended the expiration date of its previously announced offers to holders of Qorvo Notes (as defined herein) to exchange (the “Exchange Offers”) any and all outstanding 4.375% Senior Notes due 2029 (the “2029 Qorvo Notes”) and any and all outstanding 3.375% Senior Notes due 2031 (the “2031 Qorvo Notes” and, together with the 2029 Qorvo Notes, the “Qorvo Notes”) issued by Qorvo, Inc. (“Qorvo”) as set forth in the table below for (1) with respect to the 2029 Qorvo Notes, up to $850,000,000 aggregate principal amount of new 4.375% Senior Notes due 2029 (the “New 2029 Skyworks Notes”) issued by Skyworks and (2) with respect to the 2031 Qorvo Notes, up to $700,000,000 aggregate principal amount of new 3.375% Senior Notes due 2031 (together with the New 2029 Skyworks Notes, the “New Skyworks Notes”) issued by Skyworks.

Extension of Expiration Date

The Expiration Date of the Exchange Offers and the Withdrawal Deadline were previously extended to 5:00 p.m., New York City time, on September 11, 2026.

Skyworks has further extended the Expiration Date and the Withdrawal Deadline to 5:00 p.m., New York City time, on September 18, 2026, subject to further extension or earlier termination or other amendment. Skyworks is hopeful that the Mergers (as defined herein) will close within the calendar year (subject to satisfaction or waiver of all closing conditions) and is preparing to close as early as within the fiscal year. However, there can be no assurances that the closing will occur on this timeline. All other terms and conditions of the Exchange Offers as set forth in the Prospectus (as defined herein) remain in full force and effect. Capitalized terms used but not defined herein have the respective meanings set forth in the Prospectus.

Participation to Date

Global Bondholder Services Corporation, the information agent for the Exchange Offers, has advised Skyworks that as of 5:00 p.m., New York City time, on September 11, 2026, the last business day prior to the announcement of the further extension of the Exchange Offers, the following respective principal amounts of each series of Qorvo Notes have been validly tendered and not validly withdrawn:

Title of Qorvo Notes /
CUSIP / ISIN No.
Principal Amount Outstanding Principal Amount Tendered Percentage
4.375% Senior Notes due 2029

Registered:

74736KAH4 /
US74736KAH41

144A:
74736KAG6 /
US74736KAG67

Regulation S:
U7471QAF1 /
USU7471QAF10

$850,000,000 $772,253,000 90.85%
3.375% Senior Notes due 2031

144A:
74736KAJ0 /
US74736KAJ07

Regulation S:
U7471QAJ3 /
USU7471QAJ32

$700,000,000 $654,035,000 93.43%

Holders of Qorvo Notes who have already validly tendered and not validly withdrawn their Qorvo Notes do not need to re-tender their notes or take any other action as a result of the extension of the Expiration Date, and their tenders remain effective. Holders of Qorvo Notes who have not yet validly tendered, or who validly tendered and validly withdrew, may tender or re-tender, as applicable, their Qorvo Notes at any time at or prior to the Expiration Date and will be eligible to receive the applicable consideration as described in the Prospectus, subject to the terms and conditions set forth in the Prospectus, including, subject to submitting a valid Early Participation VOI Number with respect to such tendered or re-tendered Qorvo Notes, the Early Participation Premium with respect to such Qorvo Notes.

Settlement Date

Subject to the terms and conditions set forth in the Prospectus, the settlement date (the “Settlement Date”) will be promptly after the Expiration Date and is expected to occur no earlier than the second business day after the closing date of the Mergers.

Additional Information

The Exchange Offers are being made pursuant to the terms and subject to the conditions set forth in Skyworks’ registration statement on Form S-4, which was declared effective on May 29, 2026, and the related final prospectus filed with the U.S. Securities and Exchange Commission (the “SEC”) on May 29, 2026 (as it may be amended or supplemented from time to time, the “Prospectus”). Capitalized terms used but not defined herein have the meanings ascribed to such terms in the Prospectus. Each Exchange Offer is conditioned upon the closing of the transactions pursuant to which Qorvo will merge with and into a subsidiary of Skyworks (the “Mergers”), with such subsidiary continuing as the surviving entity and a wholly-owned subsidiary of Skyworks, which condition may not be waived by Skyworks. The closing of the Mergers is not conditioned upon the results of the Exchange Offers.

Skyworks, in its sole discretion, may modify or terminate either Exchange Offer and may extend the Expiration Date and/or the Settlement Date with respect to either Exchange Offer, subject to applicable law. Any such modification, termination or extension by Skyworks with respect to an Exchange Offer will not automatically modify, terminate or extend the other Exchange Offer. The Exchange Offer with respect to a series of Qorvo Notes is not conditioned upon the consummation of the Exchange Offer with respect to the other series of Qorvo Notes.

The complete terms and conditions of the Exchange Offers are described in the Prospectus, a copy of which may be obtained by contacting Global Bondholder Services Corporation, the exchange agent and information agent in connection with the Exchange Offers, at (855) 654-2015 (U.S. toll-free) or (212) 430-3774 (banks and brokers) or contact@gbsc-usa.com. Questions regarding the terms and conditions of the Exchange Offers should be directed to the dealer manager, Goldman Sachs & Co. LLC, 200 West Street, New York, New York 10282, Collect: (212) 357-1452, Toll-Free: (800) 828-3182.

This press release does not constitute an offer to sell or purchase, or a solicitation of an offer to purchase or sell, any security. No offer, solicitation, purchase or sale will be made in any jurisdiction in which such an offer, solicitation, or sale would be unlawful. The Exchange Offers are being made solely pursuant to the Prospectus and only to such persons and in such jurisdictions as is permitted under applicable law.

About Skyworks

Skyworks Solutions, Inc. is empowering the wireless networking revolution. Skyworks is a leading developer, manufacturer and provider of analog and mixed-signal semiconductors and solutions for numerous applications, including aerospace, automotive, broadband, cellular infrastructure, connected home, defense, entertainment and gaming, industrial, medical, smartphone, tablet and wearables.

Skyworks is a global company with engineering, marketing, operations, sales and support facilities located throughout Asia, Europe and North America and is a member of the S&P 500® market index (Nasdaq: SWKS).

Safe Harbor Statement

This press release includes “forward-looking statements.” Forward-looking statements relate to future events, including, but not limited to, the Exchange Offers and the Mergers, as applicable. These forward-looking statements include information relating to future events, prospects, expectations and results of Skyworks (e.g., certain projections and business trends, including with respect to future sales and revenue, as well as plans for dividend payments). Forward-looking statements can often be identified by words such as “anticipates,” “estimates,” “expects,” “forecasts,” “intends,” “believes,” “plans,” “may,” “will” or “continue,” and similar expressions and variations or negatives of these words. All such statements are subject to certain risks, uncertainties and other important factors that could cause actual results to differ materially and adversely from those projected and may affect Skyworks’ future operating results, financial position and cash flows.

These risks, uncertainties and other important factors include: the risks of doing business internationally, including from trade war or trade protection measures (e.g., tariffs, retaliatory tariffs and other countermeasures or taxes), increased import/export restrictions and controls (e.g., Skyworks’ ability to obtain foreign-sourced raw materials, including from Chinese-based sources, as well as Skyworks’ ability to sell products to certain specified foreign entities only pursuant to a limited export license from the U.S. Department of Commerce), the susceptibility of the semiconductor industry and the markets addressed by Skyworks’, and Skyworks’ customers’, products to economic cycles or changes in economic conditions, including inflation and recession that could result from trade war or trade protection measures; Skyworks’ reliance on a small number of key customers for a large percentage of Skyworks’ sales; decreased gross margins and loss of market share as a result of increased competition; Skyworks’ ability to obtain design wins from customers; Skyworks’ ability to convert design wins into revenue; market acceptance of Skyworks’ products and Skyworks’ customers’ products, including market acceptance of new, emerging technologies such as AI; the mix and volume of phone models sold by Skyworks’ largest customer; the potential impacts on Skyworks’ business, reputation, relationships, results of operations, cash flows and financial condition as a result of the Mergers and related transactions with Qorvo; the possibility that expected benefits related to such transactions with Qorvo may not materialize as expected; such transactions with Qorvo being timely completed, if completed at all; regulatory approvals required for the Mergers and related transactions not being timely obtained, if obtained at all, or being obtained subject to conditions; Skyworks or Qorvo’s business experiencing disruptions as a result of the Mergers and related transactions or due to transaction-related uncertainty or other factors making it more difficult to maintain relationships with employees, customers, other business partners or governmental entities; Skyworks and Qorvo being unable to successfully implement integration strategies or to achieve expected synergies and operating efficiencies within the expected time-frames or at all; the costs, fees, expenses and other charges related to the Mergers and related transactions with Qorvo, including with respect to any related litigation; reduced flexibility in operating Skyworks’ business as a result of the substantial amount of additional indebtedness Skyworks has incurred and expects to incur in connection with the Mergers and related transactions; delays in the deployment of commercial 5G networks or in consumer adoption of 5G-enabled devices; the volatility of Skyworks’ stock price; changes in laws, regulations and/or policies that could adversely affect Skyworks’ operations and financial results, the economy and Skyworks’ customers’ demand for Skyworks’ products, or the financial markets and Skyworks’ ability to raise capital; fluctuations in Skyworks’ manufacturing yields due to Skyworks’ complex and specialized manufacturing processes; Skyworks’ ability to develop, manufacture and market innovative products, avoid product obsolescence, reduce costs in a timely manner, transition Skyworks’ products to smaller geometry process technologies and achieve higher levels of design integration; the quality of Skyworks’ products and any defect remediation costs; Skyworks’ products’ ability to perform under stringent operating conditions; the availability and pricing of third-party semiconductor foundry, assembly and test capacity, raw materials, including rare earth and similar minerals, supplier components, equipment and shipping and logistics services, including limits on Skyworks’ customers’ ability to obtain such services and materials; risks that Skyworks may not be able to optimize Skyworks’ manufacturing footprint and achieve any financial and operational benefits from such efforts, including reducing fixed costs or improving utilization rates, disruptions to Skyworks’ manufacturing processes, including relating to any relocation of Skyworks’ key facilities; Skyworks’ ability to successfully manage Skyworks’ senior management transitions; Skyworks’ ability to retain, recruit and hire key executives or the departure of any such executives, technical personnel and other employees in the positions and numbers, with the experience and capabilities, and at the compensation levels needed to implement Skyworks’ business and product plans; the timing, rescheduling or cancellation of significant customer orders and Skyworks’ ability, as well as the ability of Skyworks’ customers, to manage inventory; other economic, social, military and geopolitical conditions in the countries in which Skyworks, Skyworks’ customers or Skyworks’ suppliers operate, including the conflicts in Ukraine, Iran and other regions in the Middle East, possible disruptions in transportation networks, and fluctuations in foreign currency exchange rates; the effects of global health crises on business conditions in Skyworks’ industry, including the risk of significant disruptions to Skyworks’ business operations, as well as negative impacts to Skyworks’ financial condition; Skyworks’ ability to prevent theft of Skyworks’ intellectual property, disclosure of confidential information or breaches of Skyworks’ information technology systems; uncertainties of litigation, including Skyworks’ ongoing securities litigation, potential disputes over intellectual property infringement and rights, as well as payments related to the licensing and/or sale of such rights; Skyworks’ ability to continue to grow and maintain an intellectual property portfolio and obtain needed licenses from third parties; Skyworks’ ability to make certain investments and acquisitions, integrate companies Skyworks acquires and/or enter into strategic alliances; and other risks and uncertainties, including those detailed from time to time in Skyworks’ filings with the Securities and Exchange Commission.

The forward-looking statements contained in this press release are made only as of the date hereof, and Skyworks undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise.

Note to Editors: Skyworks and the Skyworks symbol are trademarks or registered trademarks of Skyworks Solutions, Inc., or its subsidiaries in the United States and other countries. Third-party brands and names are for identification purposes only and are the property of their respective owners.

Additional Information about the Mergers and Where to Find It

In connection with the Mergers, Skyworks has filed with the SEC a registration statement on Form S-4, which includes a proxy statement of Qorvo that also constitutes a prospectus for the shares of Skyworks common stock to be offered in the Mergers (collectively, the “Mergers Registration Statement and Proxy Statement/Prospectus”). Each of Skyworks and Qorvo may also file other relevant documents with the SEC regarding the Mergers. This communication is not a substitute for the proxy statement/prospectus or registration statement or any other document that Skyworks or Qorvo may file with the SEC. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE MERGERS REGISTRATION STATEMENT AND PROXY STATEMENT/PROSPECTUS AND ANY OTHER RELEVANT DOCUMENTS THAT MAY BE FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THESE DOCUMENTS, CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION ABOUT SKYWORKS, QORVO, THE MERGERS AND RELATED MATTERS.

Investors and security holders can obtain free copies of the Mergers Registration Statement and Proxy Statement/Prospectus and other documents containing important information about Skyworks, Qorvo and the Mergers filed with the SEC through the website maintained by the SEC at www.sec.gov. The documents filed by Skyworks with the SEC also may be obtained free of charge at Skyworks’ website at https://www.skyworksinc.com/investors or upon written request to Skyworks at investor.relations@skyworksinc.com. The documents filed by Qorvo with the SEC also may be obtained free of charge at Qorvo’s website at https://ir.qorvo.com/ or upon written request to Qorvo at investor-relations@qorvo.com.

Media Relations:
Constance Griffiths
(949) 230-4867
Constance.Griffiths@skyworksinc.com
Investor Relations:
Raji Gill
(949) 508-0973
Raji.Gill@skyworksinc.com

PITTSBURGH, Sept. 11, 2026 (GLOBE NEWSWIRE) — Axe Compute Inc. (NASDAQ: AGPU) (the “Company”) today announced that it has granted a non-qualified stock option to purchase 60,000 shares of the Company’s common stock to one non-executive individual as an inducement material to the individual’s acceptance of employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The option was not granted under the Company’s 2024 Equity Incentive Plan.

The stock option has an exercise price of $10.67 per share and a grant date of September 7, 2026. The option has a ten-year term and vests as follows: one-third of the shares subject to the option vest on the one-year anniversary of the grant date, and the remaining shares vest in equal monthly installments over the following twenty-four months, in each case subject to continued service through the applicable vesting date.

About Axe Compute

Axe Compute Inc. (NASDAQ: AGPU) is a neocloud AI infrastructure platform built on a fundamental premise: AI innovation should not be constrained by hardware choice or availability. The company provides enterprises and AI innovators with flexibility across hardware, geography, and deployment models through two core offerings: Axe Compute Access, delivering high-performance GPU infrastructure across global locations, and Axe Compute Build, enabling the design, deployment, ownership, and operation of large-scale, dedicated AI infrastructure worldwide. Axe Compute is headquartered in Pittsburgh, Pennsylvania. For more information, visit axecompute.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other applicable securities laws. Forward-looking statements are statements other than statements of historical fact and can be identified by words such as “believe,” “expect,” “anticipate,” “plan,” “intend,” “estimate,” “project,” “will,” “may,” “should,” “would,” “could,” “target,” “forecast,” “seek,” “continue,” and similar expressions.

Forward-looking statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially, including risks described in Axe Compute’s filings with the U.S. Securities and Exchange Commission. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date of this release. Axe Compute undertakes no obligation to update them, except as required by law.

Media and Investor Relations Contact
Erin McMahon
ir@axecompute.com

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.